Anil is the CEO at Adalvo, CCO of Alvotech and Chairman of the Board at Arphio. Anil comes with an impressive track record as a CEO, P&L owner, commercial operations professional and expert negotiator, completing countless license, acquisition, supply, distribution, and sales and marketing agreements, worth >$25B. Over the course of his 15-year career in the pharmaceutical industry, Anil developed an extensive network and deep expertise in Commercial Operations, BD and M&A. Anil plays an integral role in building and establishing Adalvo as one of the leading B2B companies in Europe.
Anil previously served as the Head of Global Licensing for HELM AG where he managed all partnerships for small molecules in addition to biosimilars through a joint venture with Gedeon Richter, resulting in the most successful commercial performance in the company’s 40-year history. He also held positions of increasing responsibility at Abdi Ibrahim, in various regions and functions, eventually heading all international market operations where he developed and led the successful execution of a global market entry strategy including more than 30 new markets. He began his career at Sanofi as a medical rep and transitioned to business development.
Anil holds an MBA from the Vienna University of Economics and Business and a Master of Marketing Management from Galatasaray University. He completed a Bachelor of Engineering with a double major in Mathematics and Computer Engineering, graduating with honors. He has continued honing his skillset through various executive education programs at Harvard and INSEAD.
Anil was recognized “Leader of the Year” at the 2021 Global Generics and Biosimilars Awards.